Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
PharmacofMRI of Anxiolytic Medications (Pregabalin)
This study is currently recruiting participants.
Verified by University of California, San Diego, June 2008
Sponsors and Collaborators: University of California, San Diego
National Institute of Mental Health (NIMH)
Information provided by: University of California, San Diego
ClinicalTrials.gov Identifier: NCT00706836
  Purpose

The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. We hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.


Condition Intervention Phase
Anxiety Disorders
Drug: pregabalin
Drug: placebo
Phase IV

MedlinePlus related topics: Anxiety MRI Scans
Drug Information available for: Pregabalin
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Randomized, Single Blind (Subject), Crossover Assignment
Official Title: PharmacofMRI of Anxiolytic Medications (Pregabalin)

Further study details as provided by University of California, San Diego:

Primary Outcome Measures:
  • To evaluate the effect of an anxiolytic drug versus placebo on brain activity at rest and during emotional stimuli using fMRI and clinical scales. [ Time Frame: Week 1, 2, 3 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the effects of an anxiolytic drug versus placebo on eye blink startle response at rest and during emotional stimuli (anxiety potentiated startle, APS) as well as on clinical scales. [ Time Frame: Week 1, 2, 3 ] [ Designated as safety issue: No ]

Estimated Enrollment: 15
Study Start Date: June 2008
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Pregabalin oral tablets (50 mg)
Drug: pregabalin
One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
2: Active Comparator
Pregabalin oral tablets (200 mg)
Drug: pregabalin
One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
3: Placebo Comparator Drug: placebo
One dose of matched oral placebo to be administered one hour prior to fMRI scan

Detailed Description:

Increased amygdala and insula activity have been implicated in neurobiological models of anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to decrease activation in these areas during the processing of emotional stimuli. This study aims to replicate those results but by using a different medication, pregabalin. An eventual aim of this study, in combination with future studies, is to evaluate the utility of fMRI as a tool to identify anxiolytic function in both established and novel compounds that may be used to treat anxiety.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male, or female (not pregnant or intending to become pregnant during the study)
  • Between the ages of 18-30.
  • In good general health.
  • No specific contraindications to the drug being administered

Exclusion Criteria:

  • Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety disorder
  • Subjects who meet criteria for substance abuse or dependence within the last 6 months
  • Subjects with an positive urine screen for illicit drugs having clinically significant abnormal laboratory, ECG or physical examination findings not resolved by the baseline visit
  • Patients who have taken psychotropic drugs or antidepressants (including monoamine oxidase inhibitors, MAOI's) within the last year
  • Subjects who are left-handed.
  • Subjects suffering suffers from claustrophobia, or phobia for injections or blood
  • Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal worker/welder; history of eye surgery/eyes washed out because of metal, aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, subjects who are in the first trimester of pregnancy, subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00706836

Contacts
Contact: Lakshmi Ravindran, MD 858-534-7352 lravindran@ucsd.edu
Contact: Murray B Stein, MD,MPH mstein@ucsd.edu

Locations
United States, California
University of California, San Diego Recruiting
La Jolla, California, United States, 92037
Contact: Lakshmi Ravindran, MD     858-534-7352     lravindran@ucsd.edu    
Principal Investigator: Murray B Stein, MD, MPH            
Principal Investigator: Martin Paulus, MD            
Sub-Investigator: Lakshmi Ravindran, MD            
Sponsors and Collaborators
University of California, San Diego
Investigators
Principal Investigator: Murray B Stein, MD, MPH University of California, San Diego
  More Information

Publications:
Responsible Party: University of California, San Diego ( Murray B. Stein )
Study ID Numbers: UCSD IRB 060407 - B
Study First Received: June 26, 2008
Last Updated: June 27, 2008
ClinicalTrials.gov Identifier: NCT00706836  
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Diego:
anxiety
functional magnetic resonance imaging
fMRI
pregabalin
Lyrica

Study placed in the following topic categories:
Anxiety Disorders
Mental Disorders
Pregabalin

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Anticonvulsants
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009